AbbVie (ABBV) signed a letter of intent with the pan-Canadian Pharmaceutical Alliance for its Elahere ovarian cancer treatment, moving it closer to public drug plan coverage in Canada, with provincial and territorial listings to follow, the company said on Wednesday.
Elahere, also known as mirvetuximab soravtansine, treats ovarian cancer that resists platinum chemotherapy and whose tumors carry the folate receptor alpha protein after one to three earlier treatment courses, the company said.
It is the first targeted treatment on its own to show longer survival than single-agent chemotherapy in that group, AbbVie said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments